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Purpose: Multidimensional unfolding is a multivariate method to assess preferences using a 
small sample size, a geometric model locating individuals and alternatives as points in a joint 
space. The objective was to evaluate relapsing–remitting multiple sclerosis (RRMS) patient 
preferences toward key disease-modifying therapy (DMT) attributes using multidimensional 
unfolding.
Patients and methods: A cross-sectional pilot study in RRMS patients was conducted. Drug 
attributes included relapse prevention, disease progression prevention, side-effect risk and route 
and schedule of administration. Assessment of preferences was performed through a five-card 
game. Patients were asked to value attributes from 1 (most preferred) to 5 (least preferred).
Results: A total of 37 patients were included; the mean age was 38.6 years, and 78.4% were 
female. Disease progression prevention was the most important factor (51.4%), followed by 
relapse prevention (40.5%). The frequency of administration had the lowest preference rating 
for 56.8% of patients. Finally, 19.6% valued the side-effect risk attribute as having low/very 
low importance.
Conclusion: Patients’ perspective for DMT attributes may provide valuable information to 
facilitate shared decision-making. Efficacy attributes were the most important drug characteris-
tics for RRMS patients. Multidimensional unfolding seems to be a feasible approach to assess 
preferences in multiple sclerosis patients. Further elicitation studies using multidimensional 
unfolding with other stated choice methods are necessary to confirm these findings.
Keywords: multiple sclerosis, multidimensional unfolding, patient preferences, disease-
modifying therapy, decision-making
Introduction
Multiple sclerosis (MS) is a chronic autoimmune, inflammatory neurological disease 
of the central nervous system.1 Despite no curative treatment for MS, the past 2 
decades have seen 12 different disease-modifying therapies (DMTs) being approved 
for relapsing–remitting MS (RRMS).2 However, treatment decisions are becoming 
more challenging due to the more diverse risk-benefit spectrum associated with 
new DMTs.3
Incorporating patient characteristics and preferences is crucial to achieve personal-
ized MS treatment.4 Patients are increasingly demanding a more active role in their 
medical care. Thus, in the management of MS, it is important to involve patients in 
shared decision-making processes related to their treatment initiation or switching due 
to the unique risk-benefit profile associated with each DMT.5
correspondence: Jorge Maurino
Medical Department, roche Farma sA, 
eucalipto 33, Madrid 28016, spain
Tel +34 91 324 8173
email jorge.maurino@roche.com 
Journal name: Patient Preference and Adherence
Article Designation: Original Research
Year: 2017
Volume: 11
Running head verso: Sempere et al





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





In the real-world setting, patients evaluate a range of 
features to make decisions. The analysis of preferences can 
be used to further improve the knowledge of which treatment 
attributes are considered the most valuable by patients.6,7 
There are different methodologies for assessing patient 
preferences for treatment alternatives based on the descrip-
tion of main attributes. The conjoint analysis, a multivariate 
technique originally used to estimate the value that people 
give to the attributes that define products and services, is 
commonly utilized in health care research to determine the 
relative weight of significant attributes that comprehensively 
define the conceptual framework underlying preferences for 
a given treatment.8 Multidimensional unfolding is a method 
that allows both subjects and stimuli to be presented graphi-
cally in a common plane according to their preferences.9–11 
This methodology would permit the exploration of patient 
preferences for different attributes with a small sample size 
while providing robust results, thus overcoming the difficulty 
of large sample sizes needed in classical methods such as 
conjoint analysis.9
The main objective of this pilot study was to assess patient 
preferences for a range of DMT attributes for RRMS using 
a multidimensional unfolding approach.
Patients and methods
A noninterventional, cross-sectional pilot study was con-
ducted in adult patients with a diagnosis of RRMS (2010 
McDonald criteria), an Expanded Disability Status Scale 
(EDSS) score of 0–6.0, and who were receiving a DMT.12,13 
The study was performed in the MS clinic of a university 
hospital, and patients were consecutively included between 
September and October 2015. The study was conducted 
according to the principles of the Declaration of Helsinki and 
approved by the Institutional Review Board of the Hospital 
General Universitario de Alicante (Alicante, Spain). All 
patients provided written informed consent to participate 
in this study.
Sociodemographic and clinical characteristics of the 
sample and patient-reported questionnaires were also 
collected. The EDSS was used to measure their level of 
disability. Health-related quality of life (HRQoL) was 
assessed using the EuroQol Five Dimensions Questionnaire 
(EQ-5D).14 Patient perceptions of how well clinician per-
formance fitted the shared decision-making process was 
evaluated with the nine-item Shared Decision-Making 
Questionnaire (SDMQ-9), a patient-reported outcome tool 
ranging from 0 to 100 with higher scores indicating a greater 
extent of shared decision-making.15
DMT attributes were developed through a review of cur-
rent clinical trial literature and advanced clinical expertise.2,16 
A total of five attributes were finally defined taking into 
account the most important characteristics of available 
DMTs: relapse prevention, disease progression prevention, 
side-effect risk, route of administration and frequency of 
administration. The elicitation survey was performed through 
a five-card game. Patients were asked to rank the described 
attributes from 1 (most preferred) to 5 (least preferred).
Patient preferences were analyzed using multidimen-
sional unfolding, a simple geometric and exploratory method 
in which each drug attribute is ordered according to patient 
preferences and converted into Euclidean distances in a 
dimensional space. The attributes and patients are therefore 
represented together, thus allowing the distance of each indi-
vidual to the attribute to be directly related to their preference. 
Under this approach, each patient will remain closer to his/
her most preferred attribute.11,17
Descriptive analysis of the sample and the multidimen-
sional unfolding were conducted using the SPSS V20.0 and 
PREFSCAL.
Results
A total of 37 patients were included in the study. The mean 
age was 38.6±2.0 years, and 78.4% were female. The mean 
time since MS diagnosis was 8.8±1.1 years, and median EDSS 
score was 2.0±1.5. The most common DMTs were first-line 
injectable agents (43.2% of patients), followed by dimethyl 
fumarate (24.3%), and natalizumab (16.2%). The main 
sociodemographic and clinical characteristics of the sample 
are presented in Table 1.
The HRQoL outcome indicated a moderate-to-high 
self-assessed health status with a mean visual analog scale 
(VAS) score of 76.7±15.5. Most patients considered that their 
involvement in their treatment decision-making was adequate 
(mean SDMQ-9 total score of 81.6±3.2; Figure 1).
Figure 2 shows a graphical representation of preferences 
by means of the distance between patients’ stated preferences: 
white dots represent the responses of each participant with 
their corresponding numerical identification and the attributes 
considered. Most patients were concentrated around disease 
progression prevention (51.4%) representing the most relevant 
DMT domain. More specifically, the relative importance 
of each attribute is shown in Figure 3: disease progression 
prevention was followed by relapse prevention (40.5%). The 
frequency of administration had the lowest preference for 
56.8% of the patients, while 21.6% of them valued the side-
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Multidimensional unfolding approach to assess Ms patient preferences
this is the first study applying multidimensional unfolding 
in the field of MS care.
Several studies that identified MS DMT patient prefer-
ences have been published in the last years.21–26 However, 
limitations such as non-representative patient sampling, 
incomplete exploration of drug attribute spectrum and the 
application of heterogeneous analytical methods have limited 
generalizability. The findings from the current study are 
aligned with recent publications using conjoint analysis but 
requiring higher samples. In a sample of 651 patients from 
the USA, the most important DMT factor was identified as 
a delay in years to disability progression, followed by the 
risk of progressive multifocal leukoencephalopathy.21 Poulos 
et al22,23 conducted two studies identifying the number of 
years until MS symptoms get worse as being the most impor-
tant attribute, followed by flu-like symptoms, frequency of 
injections per month and number of relapses in the following 
years. In another study, 55 patients with RRMS completed a 
survey showing the highest preference for DMT that would 
improve MS symptoms and prevent progression, but not on 
relapse prevention.24 Furthermore, a study using latent class 
modeling conducted in Canada, with a sample of 189 patients 
with RRMS and primary progressive MS, concluded that the 
most important drug attribute was the avoidance of serious 
adverse effects.25 In summary, symptom improvement and 
prevention of disease progression were the most sought-after 
benefits related to a DMT preference. However, Wilson 
et al16 identified that patients receiving the first-generation 
DMTs showed more aversion to fatal safety risk than those 
receiving the high-efficacy DMTs, fingolimod or natali-
zumab. The ability of natalizumab-treated patients to assume 
therapy-associated risks and the factors involved in such risk 
acceptance was assessed in a study by Tur et al.26 The authors 
defined risk acceptance as a multifactorial phenomenon 
which is partly explained by an adaptive process involving 
the perception of MS as a more severe disease.
Limitations
Our pilot study has several limitations. First, it is a single-
center study. Second, the assessment of DMT attributes 
in terms of comprehension and importance by the target 
population in a previous phase before conducting the study 
was not performed. Third, the population was composed of 
a sample of clinically stable patients (a mean of 5 years since 
the last relapse) with mild disability, mostly employed and 
with a good self-perception of their health status. Therefore, 
the results may not be generalizable to less stable subjects. 
Finally, we did not include psychiatric comorbidity and 
Table 1 sociodemographic and clinical characteristics of the sample
Characteristics N=37
Age, years, mean (sD) 38.6 (2.0)
Female, n (%) 29 (78.4)
level of education, n (%)
Primary school 10 (27.0)
secondary school 13 (35.1)
University 14 (37.8)
employment status, n (%)
employed 18 (48.6)
Unemployed 9 (24.3)
retired (due to Ms) 6 (16.2)
Unpaid activity 4 (10.8)
Time since Ms diagnosis, years, mean (sD) 8.5 (1.1)
number of relapses since diagnosis, mean (sD) 2.17 (0.5)




Time since last relapse, months, mean (sD) 60.8 (7.2)
eDss score, median (sD) 2.0 (1.5)
sDMQ-9, mean (sD) 81.6 (19.8)
current DMT treatment, n (%) 
Injectable first-line DMTs 16 (43.2)
Dimethyl fumarate 9 (24.3)
Fingolimod 4 (10.8)
Time on current DMT, years, mean (sD) 4.0 (0.6)




Abbreviations: DMT, disease-modifying therapy; eDss, expanded Disability status 
scale; Ms, multiple sclerosis; sD, standard deviation; sDMQ-9, nine-item shared 
Decision-Making Questionnaire.
Discussion
A recent systematic review of qualitative and quantitative 
research to understand the experiences of health care profes-
sional (HCP)–patient interactions in MS shows that patients 
are given limited opportunity and choice for decisions about 
involvement in their treatment and care.18 Involving MS 
patients in the decision-making process is crucial for selecting 
the treatment that best suits the patients’ objectives, prefer-
ences and lifestyles.5,19,20 Our pilot study using multidimen-
sional unfolding suggests that efficacy is the most important 
drug attribute for almost all participating patients. In contrast, 
the frequency and route of administration appear to be the 
least important characteristics for DMT selection.
There are different methodologies for assessing patient 
preferences for treatment alternatives. The conjoint analy-
sis is the most commonly utilized in health care research.8 
The multidimensional unfolding is an alternative approach 
consisting in a geometric model that isolates individuals and 
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Figure 1 results of the sDMQ-9.
Abbreviation: sDMQ-9, nine-item shared Decision-Making Questionnaire.
Figure 2 Joint plot for preference rankings of DMT attributes.
Abbreviations: Ae, adverse events; AF, administration form; As, administration 
schedule; DMT, disease-modifying therapy; EP, efficacy – progression; ER, efficacy – 
progression. Figure 3 relapsing–remitting patient preferences.
cognitive impairment as factors that might be associated 
with patient preferences.
Conclusion
Understanding which MS treatment characteristics are mean-
ingful to patients may help to improve a better HCP–patient 
interaction and shared decision-making. Multidimensional 
unfolding seems to be a feasible method with clear advan-
tages. This graphical summary for each individual patient 
is a clear representation of the real clinical setting that may 
facilitate the patients’ choice among the wide variety of avail-
able DMTs. Besides, this approach may permit the explora-
tion of patient preferences for different drug attributes with 
smaller sample sizes than classical techniques. However, 
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Multidimensional unfolding approach to assess Ms patient preferences
conjoint analysis are necessary to elucidate whether this ana-
lytical approach could be a valid and an efficient alternative 
to evaluate patient preferences toward treatments.
Disclosure
The study was funded by Roche Farma SA, Spain. Elena 
Ruiz-Beato and Jorge Maurino are employees of Roche 
Farma SA. The other authors report no conflicts of interest 
in this work.
References
 1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648): 
1502–1517.
 2. Torkildsen O, Myhr KM, Bo L. Disease-modifying treatments for 
multiple sclerosis-a review of approved medications. Eur J Neurol. 
2016;23(suppl 1):18–27.
 3. Sempere AP, Gimenez-Martinez J. Safety considerations when choosing 
the appropriate treatment for patients with multiple sclerosis. Expert 
Opin Drug Saf. 2014;13(10):1287–1289.
 4. Gafson A, Craner MJ, Mattthews PM. Personalised medicine for mul-
tiple sclerosis care. Mult Scler. 2017;23(3):362–369.
 5. Colligan E, Metzler A, Tiryaki E. Shared decision-making in multiple 
sclerosis: a review. Mult Scler. 2017;23(2):185–190.
 6. Ryan M, Scott DA, Reeves C, et al. Eliciting public preferences for 
healthcare: a systematic review of techniques. Health Technol Assess. 
2001;5(5):1–186.
 7. Fried TR. Shared decision making-finding the sweet spot. N Engl J 
Med. 2016;374(2):104–106.
 8. Bridges HP, Huber AB, Marshall D, et al. Conjoint analysis applica-
tions in health: a checklist of the ISPOR good research practices for 
conjoint analysis task force. Value Health. 2011;14(4):403–413.
 9. De Leeuw J. Multidimensional unfolding. In: Everitt BS, Howell DC, 
editors. Encyclopedia of Statistics in Behavioral Science. New York: 
Wiley; 2005:1289–1294.
 10. Zaborski A. Geometrical presentation of preferences by using unfold-
ing models. Acta Universitatis Lodziensis Folia Oeconomica. 2010; 
235:365–373.
 11. De Sarbo WS, Kim S. A review of the major multidimensional scaling 
models for the analysis of preference-dominance data in marketing. 
In: Mouthinho L, Huarng K, editors. Quantitative Modelling in Market-
ing and Management. London: World Scientific Press; 2013:3–25.
 12. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for 
multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 
2011;69(2):292–302.
 13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an 
expanded disability status scale (EDSS). Neurology. 1983;33(11): 
1444–1452.
 14. Badia X, Roset M, Monserrat S, Herdman M, Segura A. The Spanish 
version of EuroQoL: a description and its applications. Med Clin 
(Barcelona). 1999;112(suppl 1):79–85.
 15. De las Cuevas C, Perestelo-Perez L, Rivero-Santana A, Cebolla-
Martí A, Scholl I, Härter M. Validation of the Spanish version of the 
9-item Shared Decision-Making Questionnaire. Health Expect. 2015; 
18(6):2143–2153.
 16. Wilson L, Loucks A, Bui C, et al. Patient-centered decision making: 
use of conjoint analysis to determine risk-benefit trade-offs for prefer-
ence sensitive treatment choices. J Neurol Sci. 2014;344(1–2):80–87.
 17. Busing FMTA, Groenen PJF, Heiser WJ. Avoiding degeneracy in mul-
tidimensional unfolding by penalizing on the coefficient of variation. 
Psychometrika. 2005;70(1):49–76.
 18. Soundy A, Roskell C, Adams R, et al. Understanding health care 
professional-patient interactions in multiple sclerosis: a systematic 
review and thematic synthesis. Open J Ther Rehabil. 2016;4:187–217.
 19. Heesen C, Solari A, Giordano A, Kasper J, Köpke S. Decisions on 
multiple sclerosis immunotherapy: new treatment complexities urge 
patient engagement. J Neurol Sci. 2011;306(1–2):192–197.
 20. Lorefice L, Mura G, Coni G, et al. What do multiple sclerosis patients 
and their caregivers perceive as unmet needs? BMC Neurol. 2013; 
13:177.
 21. Johnson FR, Van Houtven G, Ozdemir S, Hass S, White J, Miller DW. 
Multiple sclerosis patients’ benefit-risk preferences: serious adverse 
events risks versus treatment efficacy. J Neurol. 2009;256(4):554–562.
 22. Poulos C, Kinter E, Yang JC, Bridges JF, Posner J, Reder AT. Patient 
preferences for injectable treatments for multiple sclerosis in the United 
States: a Discrete-choice experiment. Patient. 2016;9(2):171–180.
 23. Poulos C, Kinter E, Yang JC, et al. A discrete-choice experiment to 
determine patient preferences for injectable multiple sclerosis treatments 
in Germany. Ther Adv Neurol Disord. 2016;9(2):95–104.
 24. Wilson L, Loucks A, Gipson G, et al. Patient preferences for attri-
butes of multiple sclerosis disease-modifying therapies development 
and results of a ratings-based conjoint analysis. Int J MS Care. 2015; 
17(2):74–82.
 25. Lynd LD, Traboulsee A, Marra CA, et al. Quantitative analysis of 
multiple sclerosis patients’ preferences for drug treatments: a best-worst 
scaling study. Ther Adv Neurol Disord. 2016;9(4):287–296.
 26. Tur C, Tintoré M, Vidal-Jordana Á, et al. Risk acceptance in mul-





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
